The NPHP4 Gene Nephronophthisis Type 4 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at identifying mutations in the NPHP4 gene, which are implicated in the development of Nephronophthisis Type 4. Nephronophthisis is a genetic disorder characterized by the inflammation and scarring of the kidneys, leading to chronic kidney disease and potentially kidney failure. This condition is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected.
The test is crucial for early detection and management of the condition, allowing for targeted treatment strategies and improved patient outcomes. It involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of mutations in the NPHP4 gene.
At DNA Labs UAE, the cost of the NPHP4 Gene Nephronophthisis Type 4 Genetic Test is set at 4400 AED. The pricing reflects the comprehensive nature of the test, which includes not only the genetic analysis but also post-test counseling to help patients and families understand the results and their implications. This service is particularly valuable for individuals with a family history of Nephronophthisis or related symptoms, providing them with critical information for making informed decisions about their health and future.
The GLIS2 Gene Nephronophthisis Type 7 Genetic Test is a specialized diagnostic tool designed to identify mutations in the GLIS2 gene, which are implicated in the development of Nephronophthisis Type 7, a rare genetic disorder affecting the kidneys. This condition is characterized by the inflammation and scarring of kidney tissues, leading to a progressive loss of kidney function, and it typically manifests in childhood or adolescence.
The test involves the collection of a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any genetic abnormalities in the GLIS2 gene. Early diagnosis through genetic testing is crucial for the management of Nephronophthisis Type 7, as it can guide treatment decisions, inform family planning, and help in the identification of potential kidney donors among family members.
Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test is available for a cost of 4400 AED. DNA Labs UAE is renowned for its state-of-the-art technology and expertise in genetic testing, providing accurate and reliable results. Patients seeking this test may need a referral from a healthcare provider, and it is advisable to discuss any questions or concerns with a genetic counselor or a nephrologist who specializes in kidney diseases.
The NEK8 Gene Nephronophthisis Type 9 Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the NEK8 gene, which are associated with Nephronophthisis Type 9, a rare genetic disorder. This condition is characterized by kidney dysfunction that progressively leads to chronic kidney disease. Symptoms may include polyuria, polydipsia, anemia, and eventually end-stage renal disease. Early and accurate diagnosis through genetic testing is crucial for managing and potentially mitigating the progression of the disease.
Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, this test offers a comprehensive analysis of the NEK8 gene to identify any mutations indicative of Nephronophthisis Type 9. The cost of the test is set at 4400 AED, reflecting the intricate technologies and expert analysis involved in ensuring accurate and reliable results. Individuals who have a family history of kidney diseases or present symptoms related to Nephronophthisis are encouraged to undergo this test for early detection and to explore potential treatment options or lifestyle adjustments that may be beneficial.
The XPNPEP3 gene plays a crucial role in kidney function, and mutations in this gene are associated with Nephronophthisis-Like Nephropathy Type 1, a rare genetic disorder characterized by the progressive loss of kidney function. This condition often leads to end-stage renal disease, necessitating lifelong dialysis or kidney transplantation for survival. Early diagnosis through genetic testing is vital for managing the condition effectively and planning for future healthcare needs.
DNA Labs UAE offers a specialized genetic test for the XPNPEP3 gene to identify mutations linked to Nephronophthisis-Like Nephropathy Type 1. This test is crucial for individuals with a family history of the condition or those exhibiting symptoms related to kidney dysfunction, providing them with a definitive diagnosis. The test is priced at 4400 AED and is conducted using advanced genetic sequencing technologies to ensure accurate results. By opting for this test, patients and their families can gain valuable insights into their genetic predisposition to kidney diseases, enabling them to make informed decisions about their health and treatment options.
The ANOS1 gene Kallmann Syndrome Type 1 genetic test is a specialized diagnostic tool used to identify mutations in the ANOS1 gene, which are responsible for Kallmann Syndrome Type 1. This condition is characterized by a combination of delayed or absent puberty and an impaired sense of smell (anosmia). The test is crucial for confirming the diagnosis, allowing for appropriate management and treatment of the condition. Conducted at DNA Labs UAE, a leading facility in genetic testing, the test provides accurate and reliable results. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to perform this genetic analysis. By identifying the specific genetic mutation, this test plays a vital role in understanding the condition better and tailoring personalized treatment plans for affected individuals.
The FGFR1 Gene Kallmann Syndrome Type 2 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the FGFR1 gene that are associated with Kallmann Syndrome Type 2. Kallmann Syndrome is a genetic condition characterized by delayed or absent puberty and an impaired sense of smell, resulting from a combination of hormonal and neurological anomalies. The FGFR1 gene plays a crucial role in the development of the olfactory system and the hypothalamic area of the brain, which are integral to the sense of smell and the regulation of reproductive hormones.
This genetic test is pivotal for individuals showing symptoms of Kallmann Syndrome or those with a family history of the condition, as it provides a definitive diagnosis by identifying mutations in the FGFR1 gene. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to look for genetic alterations.
Offered at a cost of 4400 AED, the FGFR1 Gene Kallmann Syndrome Type 2 Genetic Test at DNA Labs UAE is a crucial step towards personalized treatment and management plans for affected individuals. It not only helps in confirming the diagnosis but also aids in understanding the risk of passing the condition to future generations, thereby facilitating informed family planning decisions.
The PROK2 Gene Kallmann Syndrome Type 4 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to detect mutations in the PROK2 gene, which are associated with Kallmann Syndrome Type 4. Kallmann Syndrome is a genetic condition characterized by the combination of delayed or absent puberty and an impaired sense of smell (anosmia). Type 4 of this syndrome, specifically linked to mutations in the PROK2 gene, highlights the importance of genetic testing for accurate diagnosis and management.
This test is crucial for individuals displaying symptoms of Kallmann Syndrome or those with a family history of the condition, as it provides definitive genetic evidence of the syndrome. The process involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of genetic mutations in the PROK2 gene.
The cost of the PROK2 Gene Kallmann Syndrome Type 4 Genetic Test at DNA Labs UAE is set at 4400 AED. This investment covers the comprehensive analysis required to identify the genetic alterations responsible for the condition, offering a pathway towards personalized treatment and management strategies for affected individuals. By pinpointing the genetic basis of the syndrome, healthcare providers can offer targeted advice and interventions, significantly improving the quality of life for those diagnosed with Kallmann Syndrome Type 4.
The SEMA3A gene plays a crucial role in the development of the nervous system and has been linked to Kallmann Syndrome, a genetic condition characterized by the failure to start or fully complete puberty, combined with an impaired sense of smell (anosmia). This condition results from the abnormal development of certain neurons that are essential for the release of sex hormones. Mutations in the SEMA3A gene disrupt the normal signaling pathways necessary for neuronal development, leading to the symptoms observed in Kallmann Syndrome.
To diagnose and confirm the presence of SEMA3A-related Kallmann Syndrome, genetic testing is available at DNA Labs UAE. This specialized test involves analyzing the patient's DNA to identify mutations in the SEMA3A gene that are known to cause the condition. The process is comprehensive, ensuring accurate diagnosis which is crucial for the management and treatment of the syndrome.
The cost of the SEMA3A related genetic test at DNA Labs UAE is 4400 AED. This test is a valuable tool for individuals with a clinical diagnosis or symptoms suggestive of Kallmann Syndrome, as well as for family members of affected individuals who may be at risk. Early and accurate diagnosis through genetic testing can significantly improve the quality of life for those affected by providing appropriate treatment options and genetic counseling.
The GHR Gene Laron Syndrome Genetic Test is a specialized diagnostic tool designed to identify mutations in the Growth Hormone Receptor (GHR) gene, which are indicative of Laron Syndrome. This rare genetic disorder is characterized by a resistance to growth hormone, leading to short stature and other physical anomalies. The test is a crucial step in diagnosing the syndrome, allowing for appropriate management and treatment strategies to be implemented.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test ensures accuracy and reliability in results. The cost of the GHR Gene Laron Syndrome Genetic Test is 4400 AED, reflecting the comprehensive analysis and expertise required to diagnose this rare condition. Through this test, individuals suspected of having Laron Syndrome can gain valuable insights into their genetic makeup, enabling informed decisions regarding their health and well-being.
The SCNN1B gene Liddle syndrome genetic test is a specialized diagnostic procedure aimed at identifying mutations in the SCNN1B gene, which are associated with Liddle syndrome. Liddle syndrome is a rare autosomal dominant disorder characterized by early-onset hypertension, hypokalemia, and decreased plasma renin activity. This condition arises from mutations that lead to increased activity of the epithelial sodium channel (ENaC) in the kidneys, resulting in excessive sodium reabsorption and potassium loss.
The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in a laboratory setting to identify any genetic abnormalities in the SCNN1B gene. Given its specificity, this test is crucial for confirming a diagnosis of Liddle syndrome, differentiating it from other forms of hypertension, and guiding appropriate treatment strategies.
At DNA Labs UAE, the SCNN1B gene Liddle syndrome genetic test is available for a cost of 4400 AED. DNA Labs UAE is a reputable facility equipped with advanced genetic testing technologies and staffed by experienced professionals. By opting for this test at DNA Labs UAE, patients can expect accurate results, which are essential for managing Liddle syndrome effectively and improving patient outcomes.
